6615 SOFIVA GENOMICS

Chairman Yi-Ning Su 2017.01.04 Company Profile SOFIVA GENOMICS

Founded in July, 2012, SOFIVA GENOMICS focuses on clinical needs to develop next-generation testing models in genomic medicine

Maternal-Fetal Medicine Genomic Medicine Clinical Medicine

We have Asia’s leading laboratory to provide comprehensive services to those in need Our Orientation

￭ Mothers and fetuses Targets ￭ Individuals with genetic diseases ￭ Individuals with cancer ￭ Healthy individuals

￭ Mothers and fetuses: Helping mothers successfully conceive and safely give birth to healthy babies ￭ Individuals with genetic diseases: Helping doctors in giving patients swift and accurate diagnoses and treatments Service Orientation ￭ Individuals with cancer: Facilitating the detection, prognosis, and tracking of cancer so that doctors can treat and monitor their patients more accurately ￭ Healthy individuals: Grasping their genetic health and risk of contracting disease and early planning for health promotion

￭ Now: Technology and platform combining biochemical detection + gene chip Technical + next-generation sequencing to provide customers with comprehensive Development testing services ￭Future: Development of comprehensive and customized testing using a single sample and a single platform

￭ Business promotion: Joint promotion and hospitals, introduction to medical personnel, onsite recommendations, promotion at foreign Marketing and domestic conferences/expos Channels ￭ PR promotion: online/Facebook marketing, literature and posters to promote health education, print media publicity, PR invitations

Market ￭ Rooting in Taiwan market Developing China and South Eastern Asia market Development Branching into global market Award-Winning Recognition

◆ Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Awards ◆ National Innovation Award ◆ National & Medical Care Quality Award ◆ The National Brand Yushan Award ◆ ROC Consumer Health and Safety Organization Number One Brand Award ◆ SNQ Symbol of National Quality International Standard Certifications ◆ ISO 9001 Certification ◆ ISO/IEC 17025 Certification ◆ US College of American Pathologists (CAP) Laboratory Proficiency Testing ◆ The only certified technical partner of illumina® International Cooperation and Exchange Competitive Advantages Pioneer of Genetic Diagnosis

Pioneer in Asia First team in Asia to implement preimplantation Earliest Development genetic diagnosis (PGD) and offer preimplantation genetic screening (PGS). Early implementation of aCGH technology into prenatal diagnosis. Developed gene screening First Publishing for spinal muscular atrophy (SMA). First to publish international papers on the use of PIGF, sFlt1, and hemodynamics to predict preeclampsia.

Leading Investigation Conducted leading research into genetic Pioneering Development screening for hereditary hearing loss, congenital central hypoventilation syndrome, and Pioneered genetics, research into rare disease, genetic congenital cytomegalovirus infection. disease, cancer, chronic disease, and cardiovascular disease, and introduced personalized gene testing. Genetic Testing Services

Reproductive Medicine Prenatal Genetic Test Personalized Genetic Test Rare Disease Genetic Test Genetic Test • Non-Invasive Prenatal Screening, NIPS • MyGene Cancer One • MyGene Cancer One • Preimplantation Genetic Diagnosis, • Non-Invasive Prenatal Screening+, • MyGene Cancer Screening • Achondroplasia PGD NIPS+ • MyGene Cancer Monitor • Prader Willi Syndrome, PWS • NGS-based Preimplantation • Array-Comprehensive Genomic • MyGene Hereditary Cancer • Angelman Syndrome, AS Genetic Screening, NGS-based PGS Hybridization, aCGH • MyGene Women • Rett Syndrome Neonatal Genetic • Genetic Testing • MyGene Breast Cancer • Williams-Beuren Syndrome, WBS Screening • Spinal Muscular Atrophy Carrier • MyGene Colon Cancer • DiGeorge syndrome • Hereditary Hearing Loss Screening Screening • MyGene Health • Huntington’s disease, HD • Congenital Central Hypoventilation • Fragile X Syndrome Carrier Screening • MyGene Telomere • Osteogenesis Imperfecta, OI Syndrome, CCHS • Congenital Infection Screening • MyGene50 Carrier Screening • Spinocerebellar Atrophy, SCA • Congenital Cytomegalovirus • Risk Assessment of Preeclampsia • MyGene100 Prenatal Screening • Duchenne Muscular Dystrophy, Infection Screening, CMV • Down Syndrome Screening • Molecular Testing for Lesions in DMD • Atopic Dermatitis Gene Screening •Karyotyping Colon and Rectum • Hemophilia • Human Papillomavirus Screening, • Spinal Muscular Atrophy, SMA HPV Screening • Paternity Testing We provide genetic detection • Customized Genetic Testing for more than 200 rare diseases. One-stop Shop  Lab testing completed in Taiwan Model of Service  Clinicians audit and sign off on the report  Online inquiry/APP application

Specimen collected Specimen is assigned Professional Next-generation Bioinformatics analysis is by the hospital is a unique number and technicians sequencing is used to interpret the large sent to Sofiva for tracked using a extract DNA conducted volume of sequencing testing barcode data

Report is completed Laboratory supervisor Report is issued to Electronic reports can and barcode scanning and medical specialists the hospital so the be uploaded to official finished audit and sign off on doctor can explain websites and accessed the report it to the patient using apps Operating Performance Revenue and Profit Trends

360,000 40 351,354 350,000 36 344,398 35

340,000 31 30 30 330,000

25 320,000

310,000 20

300,000 294,845 15

290,000 10 280,000

5 270,000

260,000 0 2014 2015 Jan.‐Nov.,2016

Operating revenue(Thousands of NTD) Rate of gross profit (%) Future Prospects In the foreseeable future, products associated with genetic testing will make breakthroughs in the three following areas:

Assisted Reproduction (PGD/PGS) Applied to reproductive health to significantly reduce birth defects

Noninvasive Prenatal Screening (NIPS) Screening for fetal chromosomal abnormalities or microdeletion disorder

Precision Medicine Tumor diagnosis and drug development Preimplantation Genetic Diagnosis, PGD & Preimplantation Genetic Screening, PGS

Technical Principle

With preimplantation genetic screening technology, we can inspect whether preimplantation embryos have 23 pairs of chromosomes that are structurally normal (PDS) or carry genes associated with specific genetic diseases (PGD).

Picture source :2008.02.21 United Daily News Non-Invasive Prenatal Screening (NIPS)

Technical Principle

With 10 c.c. of the expecting mother’s blood, the cell-free DNA of the fetus can be analyzed using next-generation sequencing to test the fetus for diseases resulting from abnormal chromosome numbers, including Down syndrome (T21), Edwards syndrome(T18), and Patau syndrome (T13). Non-Invasive Prenatal Screening+ (NIPS+)

Screening Upgrade

NIPS+ incorporates Taiwan’s chromosome database to perform a comprehensive analysis of chromosome numbers and 20 types of microdeletion disorders for comprehensive early screening protection! Non-invasive Liquid Biopsy for Cancer Screening

A Turning Point in Cancer Diagnosis A number of studies have proven that genetic screening We provide genetic detection for more than for CTCs can help determine the occurrence and 200 rare diseases. metastasis of cancer, assess patient prognosis and adjuvant therapy, and personalize medical advice. Analysis of the molecular changes and genes of CTCs enables doctors to have a better grasp of the dynamic changes in cancer. Needing only venous blood samples, this approach is quick and simple and provides an ideal sample source, which greatly increases its practical value.

Picture source : dreamstime.com Picture source :Nat Med. 2014 May;20(5):548-54. Forecasted Scope of Global Precision Medicine Market

1400

1200

1000

800

600

400

200

0 2015 2016 2017 2018 2019 2020

Revenue ($One hundred million)

Data source: BBC Research SOFIVA GENOMICS Keep exploring the tree of life

Thank you